Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: Survival advantage for bone marrow in all age groups

Haematologica

Volumn 97, Issue 8, 2012, Pages 1142-1148

  Bacigalupo, Andrea ^a   Socié, Gérard ^b   Schrezenmeier, Hubert ^c   Tichelli, Andre ^d   Locasciulli, Anna ^e   Fuehrer, Monika ^f   Risitano, Antonio M ^g   Dufour, Carlo ^h   Passweg, Jakob R ^d   Oneto, Rosi ^a   Aljurf, Mahmoud ⁱ   Flynn, Catherine ^j   Mialou, Valerie ^k   Hamladji, Rose Marie ^l   Marsh, Judith C W ^m  

^a UNIVERSITY OF GENOA   (Italy)

^b SAINT LOUIS HOSPITAL   (France)

^c Institut Klinische und Transfusion Medizin   (Germany)

^d Department of Haematology ^*  (Switzerland)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f Oncology and Haematology   (Germany)

^g FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^h G GASLINI INSTITUTE   (Italy)

ⁱ KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^j ST JAMES S HOSPITAL   (Ireland)

^k IHOP   (France)

^l Centre Pierre et Marie Curie   (Algeria)

^m KING S COLLEGE HOSPITAL   (United Kingdom)

more..

Author keywords

Allogeneic transplantation; Aplastic anemia; Bone marrow transplants; Peripheral blood transplants

Indexed keywords

CD45 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGE; AGED; APLASTIC ANEMIA; ARTICLE; CAUSE OF DEATH; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE SEVERITY; GRAFT FAILURE; GRAFT INFECTION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; INCIDENCE; INFANT; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD STEM CELL; PRESCHOOL CHILD; PROPHYLAXIS; SCHOOL CHILD; SURVIVAL RATE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SIBLINGS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84864762897     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.054841     Document Type: Article

References (20)

1. Storb R, Thomas ED, Buckner CD, Clift RA, Johnson FL, Fefer A, et al. Allogeneic marrow grafting for treatment of aplastic anemia. Blood. 1974;43(2):157-80.
2. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110(4):1397-400.
3. Chu R, Brazauskas R, Kan F, Bashey A, Bredeson C, Camitta B, et al. Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. Biol Blood Marrow Transplant. 2011;17(7): 1018-24.
4. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol. 2010;11(4):331-8.
5. Eapen M, Le Rademacher J, Antin JH, Champlin RE, Carreras J, Fay J, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood. 2011;118(9):2618-21.
6. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G, et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica. 2009;94(1): 94-101.
7. Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. Br J Haematol. 2009;147(5): 614-33.
8. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942-7.
9. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-64.
10. Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006;12(5):573-84.
11. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447-54.
12. Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007;109 (10):4582-5.
13. Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI, et al. Longterm follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophos-phamide combined with antithymocyte globulin. Blood. 1997;89(10):3890-1.
14. Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998;91 (10):3637-45.
15. Ladeb S, Abdelkefi A, Torjman L, Ben Neji H, Lakhal A, Kaabi H, et al. Allogeneic hematopoietic stem cell transplantation for acquired aplastic anemia using cyclophos-phamide and antithymocyte globulin: a single center experience. Bone Marrow Transplant. 2009 Jul 27. [Epub ahead of print]
16. Marsh JC, Gupta V, Lim Z, Ho AY, Ireland R, Hayden J, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011;118 (8):2351-7.
17. Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socié G, et al. Improved out-come of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94(9):1312-5.
18. Gupta V, Eapen M, Bajorunaite R, Carreras J, Aljurf M, Gale RP, et al. Impact of age on outcomes after transplantation for acquired aplastic anemia using HLA-identical sibling donors. Haematologica. 2010;95(12):2119-25.
19. Sangiolo D, Storb R, Deeg HJ, Flowers ME, Martin PJ, Sandmaier BM, et al. Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. Biol Blood Marrow Transplant. 2010;16(10):1411-8.
20. Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007; 92(1):11-8.